pecific downside risks relate to rising cost inflation not adequately covered by reimbursement (e.g. for dialysis in the US), M&A integration (e.g. Qiransalud, Care Coordination deals) and/or overpaying for potential future acquisitions, more-than-expected easing of drug shortages in the US and/or product